A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. - Cunningham,C.C.; Holmlund,J.T.; Schiller,J.H.; Geary,R.S.; Kwoh,T.J.; Dorr,A.; Nemunaitis,J. (Clin Cancer Res, 2000)